Our Chief Executive Officer Dr James Garner was featured in a recent article in The Australian Financial Review on the new breed of biotechnology companies.
In the interview, Dr Garner spoke about the about the importance of networks and collaborations in the biotech industry and how Kazia focuses on structuring and managing the approvals and trial stages of drug development.
The article also talks about the five ongoing trials with Kazia’s lead candidate, GDC-0084 and our recent announcement that leading US cancer treatment centre, Memorial Sloan Kettering (MSK), will use GDC-0084 in a phase I clinical trial for cancer that has spread to the brain (brain metastases).
The print version of article also featured an advertisement, highlighting Kazia’s role in the fight against brain cancer:
Read the online version of the article here.
